Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on September 30, 2020, reporting events that occurred on September 28, 2020. The Company is incorporated in Delaware and its common stock trades on The NASDAQ Global Market under the symbol "HROW".
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is a modification to the Company's Board of Directors:
- Resignation: Anthony J. Principi resigned from the Board of Directors effective immediately on September 28, 2020. The Company stated this resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment: R. Lawrence Van Horn, Ph.D., was appointed to fill the vacancy created by Mr. Principi's resignation. He will serve until the 2021 Annual Meeting of Stockholders.
Management Commentary and Compensation
Mr. Van Horn is an independent director with extensive expertise in healthcare management, economics, and policy. He will serve on the Audit, Compensation, and Nominating and Corporate Governance Committees, including as Chair of the Nominating and Corporate Governance Committee.
Regarding compensation, Mr. Van Horn will receive the Company's standard director's compensation package (cash and equity) as described in the most recent proxy statement. Additionally, he received an initial award of 12,500 restricted stock units, which will vest one year from the grant date.
Key Facts for Investor Verification
- Verify the effective date of Anthony J. Principi's resignation (September 28, 2020).
- Confirm the new board composition and committee assignments for R. Lawrence Van Horn, Ph.D.
- Review the Company's most recent proxy statement to understand the standard director compensation package referenced in this filing.
- Note that the 12,500 restricted stock units granted to Mr. Van Horn have a one-year vesting period.